The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial.
about
EFNS guidelines on neuropathic pain assessment.Viral ion channels: molecular modeling and simulation.Neurophysiology of cancer pain.Wind-up and the NMDA receptor complex from a clinical perspective.Understanding central mechanisms of acupuncture analgesia using dynamic quantitative sensory testing: a review.Postherpetic neuralgia: the never-ending challenge.Current aproach to cancer pain management: Availability and implications of different treatment options.Placebo effects in oncology.Targeting N-methyl-D-aspartate receptors for treatment of neuropathic painAnalgesia for patients with advanced disease: 2Cell signaling and the genesis of neuropathic pain.Neuropathic pain in children with cancer.Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic painEmerging analgesics in cancer pain management.Pathophysiology and management of surgical and chronic oral pain in dogs and cats.Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways.Effect of Preoperative Oral Amantadine on Acute and Chronic Postoperative Pain After Mandibular Fracture SurgeryTargeting the NMDA receptor subunit NR2B for the treatment of neuropathic painTranslational pain research: achievements and challengesNMDA receptor antagonists for the treatment of neuropathic pain.Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Cancer treatment-related neuropathic pain syndromes--epidemiology and treatment: an update.Gene therapy: a potential approach for cancer pain.Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues.A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy.Assessment and manifestation of central sensitisation across different chronic pain conditions.Neurophysiology of Cancer Pain: From the Laboratory to the Clinic.Modulation of NMDA Receptor Activity in Fibromyalgia.
P2860
Q33199137-96517856-A9D4-4772-A6B2-F4FD5D2865BAQ33536851-AFF04019-588F-400B-8CC3-765E887EBC0BQ33900381-55C17A37-CB0F-4C32-AC80-346DF33896B0Q33930954-AEE285BF-BE31-4297-9132-A5B38704BEFFQ34350575-53EAB546-7536-494D-A8F5-5C0D0AED7117Q34592574-3F5E0FE4-6208-4D75-A899-3D63971ACE08Q34779398-FB008610-6F94-4E09-AFD1-AD939A2FC77CQ35037527-E6FB982E-68F1-4BB0-A785-8A4CD66F0528Q35041376-6A848BE1-83F0-4312-A368-C290795DA2DEQ35745100-0CECB0EB-C65B-4567-9D8F-B21D8033F653Q35904210-19905590-5DE0-442C-B6D8-CA26A06FFA6DQ35913796-7E8DCA65-1D96-4E61-9D47-C6678F2D8F37Q36024535-64F29ACC-AC09-4A64-B620-3A92CC2357C4Q36066043-E55C8266-77FC-46EC-BABF-60BFB74FF588Q36485877-5C080934-C9D4-454D-9B27-6399A5A1D881Q36860042-9257F383-B28A-4153-B470-2E6A5CAF12D9Q37246134-582CE911-A8D1-426F-9797-1CFD0B5DD9F0Q37374352-B3BB8A9F-8E6E-4360-8417-6CB471B1426BQ37376539-AF72BB33-163E-41E1-87AC-7C2145E9B894Q37806320-5A9369B8-851F-4E8C-BD34-B200FB167F2CQ37907386-A147C133-018C-4A1B-AB0F-1756011CC0C1Q38190016-C3A18FC4-E183-400D-ADEE-5B07BED14CA2Q38252761-4757AD2D-0CB1-4C1D-809B-7BF43300E979Q38745962-55B77E14-B319-48C0-9F8C-B17914FCEB76Q38781226-4F8D7BD0-B5D3-427C-AB0F-E4214E44D114Q39397971-009F3F71-36DE-4C76-9263-DD7BB8C54A75Q47234803-4048124E-F5E9-4F13-AF1A-D675F170AD18Q51379157-61E767FC-CD1A-4042-9538-C6CFB0D062E3Q52093964-01074BAB-939A-4B85-A96D-EB78CC41DA06
P2860
The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
The NMDA receptor antagonist a ...... zed, placebo controlled trial.
@en
The NMDA receptor antagonist a ...... zed, placebo controlled trial.
@nl
type
label
The NMDA receptor antagonist a ...... zed, placebo controlled trial.
@en
The NMDA receptor antagonist a ...... zed, placebo controlled trial.
@nl
prefLabel
The NMDA receptor antagonist a ...... zed, placebo controlled trial.
@en
The NMDA receptor antagonist a ...... zed, placebo controlled trial.
@nl
P2093
P921
P1433
P1476
The NMDA receptor antagonist a ...... zed, placebo controlled trial.
@en
P2093
P304
P356
10.1016/S0304-3959(98)00014-1
P407
P577
1998-04-01T00:00:00Z